阿那曲唑片Anastrozole 1mg

For the treatment of advanced breast cancer in postmenopausal women. For patients with estrogen receptor-negative breast cancer, this product may be considered if they show a positive clinical response to tamoxifen. For the adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women. For the adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women who have received 2–3 years of tamoxifen adjuvant therapy.

Adults (including the elderly): 1 tablet orally once daily. Renal Impairment: No dose adjustment is required for patients with mild to moderate renal impairment. Hepatic Impairment: No dose adjustment is required for patients with mild hepatic impairment. Adjuvant Treatment for Early Breast Cancer: The recommended duration of treatment is 5 years.

Premenopausal women. Pregnant or lactating women. Patients with severe renal impairment (creatinine clearance < 30 mL/min). Patients with moderate to severe hepatic disease. Patients with known hypersensitivity to anastrozole or any of its components.

For patients with suspected hormone status, biochemical tests should be performed to confirm menopause (natural or artificial menopause). There is no data supporting the safe use of this product in patients with moderate to severe hepatic impairment or severe renal impairment (creatinine clearance < 30 mL/min). Since this product reduces circulating estrogen levels, it may lead to decreased bone mineral density and potentially increased risk of fractures. The use of bisphosphonates may prevent further decrease in bone mineral density in postmenopausal women caused by anastrozole and may be considered. Women with osteoporosis or potential osteoporosis risk should undergo regular formal bone mineral density tests (e.g., DEXA scan) before the start of treatment and periodically thereafter. Osteoporosis treatment or prevention should be initiated at an appropriate time and closely monitored. In the ATAC trial, a higher incidence of elevated serum cholesterol was reported in patients receiving anastrozole compared with those receiving tamoxifen (9% in the anastrozole group vs. 3.5% in the tamoxifen group). In the ATAC trial, an increased incidence of ischemic cardiovascular events was observed in women with pre-existing heart disease (17% in the anastrozole group vs. 10% in the tamoxifen group). Therefore, patients with a history of ischemic heart disease should use anastrozole after weighing the risks and benefits. Use with caution in athletes. This product is unlikely to affect patients' ability to drive or operate machinery. However, fatigue and drowsiness have been reported. Special attention should be paid if these symptoms persist while driving or operating machinery.

The main side effects of this product include hot flushes, vaginal dryness, increased sebum secretion, gastrointestinal disturbances (anorexia, nausea, vomiting, diarrhea), fatigue, depression, headache, or rash. Side effects are usually mild to moderate and well tolerated by patients. Uterine bleeding has been occasionally reported, mainly occurring in the first few weeks after patients switch from existing hormone therapy to this product. If bleeding persists, further evaluation is required. Changes in liver function (e.g., elevated transpeptidase and alkaline phosphatase) have been reported in patients with advanced breast cancer treated with this product, but many of these patients already had liver metastases or bone metastases. The cause of these changes has not been studied. Clinical observations show that this product can slightly increase plasma total cholesterol levels.

10 tablets per blister, 10 blisters per box.

Store in a tightly sealed container, protected from light, at 20℃–25℃. Keep out of the reach of children.